SNIPR Biome is pioneering a novel use of CRISPR/Cas technology to address human diseases. We use our technology to selectively and precisely decimate target bacteria, while leaving the rest of the microbial community intact and unharmed. SNIPR Biome utilizes the natural bacterial CRISPR-based adaptive immune system in a programmable fashion to kill target bacteria based on their specific genomes. Our drugs are next-generation antibiotics harboring DNA-based CRISPR-Guided Vectors™ (CGV™ Technology) that cause double-stranded breaks in bacterial genomes and ultra-rapid killing in a matter of minutes, allowing rapid response in acute settings.
Using SNIPR Biome’s proprietary adaptation of natural CRISPR systems, engineering can be precisely targeted to the desired bacterial species or strain whilst minimizing development of resistance to treatment. Our technology harnesses bacterial endogenous Cas nuclease activity, fatally turning the cells’ own machinery on itself. Using carefully designed CRISPR-Guided Vectors™, very selective manipulations can shape complex microbial communities, including the human gut microbiome.
“SNIPR Biome, SNIPRBIOME, Synthetic Phage Vehicle, SPV, PicoBiotics, CRISPRbiotics, CRISPR-Guided Vector, and CGV are trademarks of SNIPR Biome ApS. Our CRISPR technology is patented broadly for the use of all Cas types, including Cas3 and Cas9.”